Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2016 - 2025)

Ani Pharmaceuticals' Income from Continuing Operations history spans 15 years, with the latest figure at 27525000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 367.96% year-over-year to 27525000.0; the TTM value through Dec 2025 reached 78337000.0, up 522.94%, while the annual FY2025 figure was 78337000.0, 522.94% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 27525000.0 at Ani Pharmaceuticals, up from 26600000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 27525000.0 in Q4 2025 and bottomed at 24198000.0 in Q3 2024.
  • The 5-year median for Income from Continuing Operations is 1100500.0 (2021), against an average of 590050.0.
  • The largest annual shift saw Income from Continuing Operations crashed 23365.12% in 2022 before it skyrocketed 1144.71% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 24141000.0 in 2021, then surged by 82.53% to 4217000.0 in 2022, then soared by 127.37% to 1154000.0 in 2023, then plummeted by 990.12% to 10272000.0 in 2024, then skyrocketed by 367.96% to 27525000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Income from Continuing Operations are 27525000.0 (Q4 2025), 26600000.0 (Q3 2025), and 8531000.0 (Q2 2025).